ARAV
Aravive Inc
Halal Rating :
Last Price
$0.04
Last updated:
Market Cap
-
7D Change
0.0%
1 Year Change
0.0%
Company Overview
Industries
Exchange
Next Earnings Date
Aravive, Inc. is a clinical-stage biopharmaceutical company that develops treatments for life-threatening diseases, including cancer and fibrosis. The company's lead product candidate is batiraxcept (AVB-500), which targets the GAS6-AXL signaling pathway. Their primary focus is on developing innovative therapies for gynecologic, pancreatic, and renal cancers.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2023 | $2.76m | $11.67m | - | - | 0.00% | 0.00% |
| June 30, 2023 | $1.27m | $13.86m | - | - | 0.00% | 0.00% |
| March 31, 2023 | $1.49m | $19.4m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Aravive Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.